Prostate Cancer Campaigns Boost Enrollment in Study to Validate ClarityDX Diagnostic Test in Canada

Prostate Cancer Campaigns Boost Enrollment in Study to Validate ClarityDX Diagnostic Test in Canada
Campaigns by Movember and the Alberta Cancer Foundation have helped to raise the number of men enrolled to more than 200 in the validation study of ClarityDX Prostate, a new blood screening test developed by Nanostics for the early diagnosis of prostate cancer. Recruitment, which started in June this year, got an additional boost in November, thanks to the "Grow a Mo" (moustache) and GivingTuesday 2019 campaigns run by the two Canadian charities. "We are overwhelmed by the support we've received from people all over Alberta as we work to validate the ClarityDX Prostate test," John Lewis, Sojonky chair in prostate cancer research at the University of Alberta and CEO of Nanostics, said in a press release. "Improving the accuracy of prostate cancer screening will have a significant impact on men and their families in this province and beyond," he said. Movember is known internationally for raising funds to advance research in prostate and testicular cancer, as well as for mental health and suicide prevention in men. This November, it launched its annual "Grow a Mo" campaign to help raise awareness and funds. The Alberta Cancer Foundation is the largest charity dedicated to cancer research and care in the province of Alberta, Canada, and is supported by donors. In its GivingTuesday 2019 campaign, donations tripled their impact, thanks to matching gifts by two Alberta families who have each offered $50,000 to the foundation. ClarityDX Prostate is a noninvasive blood test designed to detect clinically significant prostate cancer early and help guide doctors on which patients to refer for biopsy. The test was designed both for diagnosis and for active surveillance, or watchful waiting, to see if patients progress to clinically significant cancer. The t
Subscribe or to access all post and page content.